Objective: This study aims to analyze risk factors for central lymph node metastasis (CLNM) in patients with small papillary thyroid carcinoma (PTC).

Methods: The clinicopathologic data of 375 patients with small PTC admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2017 to December 2020 were analyzed retrospectively. The patients were divided into two groups, namely, CLNM (n = 177) and non-CLNM (n = 198) groups. Relevant data from the two groups were analyzed using the chi-square test, logistic regression analysis, and the receiver operating characteristic (ROC) curve.

Results: The CLNM rate of the 375 patients with small PTC was 47.2%. The chi-square test revealed that CLNM status was correlated with a patient's gender and age as well as tumor size, number of lesions, and invasion of the thyroid capsule (P < 0.05), but not with BRAF gene mutation, Hashimoto's thyroiditis (HT), or nodular goiter. Multivariate analysis indicated significant differences in gender, maximum tumor diameter, multifocality, and thyroid adventitial infiltration between the two groups (all P < 0.05) but no significant difference between the two groups in regard to HT and nodular goiter. The ROC curve suggested that age ≤ 26.5 years and maximum tumor diameter ≥ 0.75 cm were thresholds for increased risk of CLNM.

Conclusions: Lymph node metastasis in the central area of small PTC is associated with multiple factors. Careful examination, analysis, and evaluation of these factors can help in developing accurate individualized treatment strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244229PMC

Publication Analysis

Top Keywords

patients small
16
lymph node
12
node metastasis
12
small ptc
12
risk factors
8
small papillary
8
papillary thyroid
8
375 patients
8
chi-square test
8
nodular goiter
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Clario, Philadelphia, PA, USA.

Background: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.

Method: ClinicalTrials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.

View Article and Find Full Text PDF

Background: Small, soluble oligomers, rather than mature fibrils, are the major neurotoxic agents in Alzheimer's disease (AD). In the last few years, Aprile and co-workers designed and purified a single-domain antibody (sdAb), called DesAb-O, with high specificity for Aβ oligomeric conformers. Recently, Cascella and co-workers showed that DesAb-O can selectively detect synthetic Aβ oligomers both in vitro and in cultured cells, neutralizing their associated neuronal dysfunction.

View Article and Find Full Text PDF

Background: Differences in patient characteristics across geographical regions may result in heterogeneity in clinical trial populations. evoke (NCT04777396) and evoke+ (NCT04777409) are two phase 3, multinational, randomised trials investigating semaglutide versus placebo in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease (AD) (early AD). We present baseline characteristics across the geographical regions in evoke/evoke+.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!